Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example

Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example

Abstract Introduction The first direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection were reimbursed via Australia’s Pharmaceutical Benefits Scheme (PBS) in March 2016. This was based on the recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) th...

Full description

Bibliographic Details
Main Authors: Emma Warren, Belinda J. C. Castles, Gillian C. Sharratt, Aitor Arteaga
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-03-01
Series:Infectious Diseases and Therapy
Subjects:
Economic modeling
Cost-effectiveness
Health technology assessment
Hepatitis C
Australia
Online Access:https://doi.org/10.1007/s40121-024-00926-1

Similar Items

Similar Items